Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Maxcyte Inc (MXCT)

Maxcyte Inc (MXCT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 377,629
  • Shares Outstanding, K 105,483
  • Annual Sales, $ 41,290 K
  • Annual Income, $ -37,920 K
  • EBIT $ -42 M
  • EBITDA $ -45 M
  • 60-Month Beta 1.37
  • Price/Sales 9.27
  • Price/Cash Flow N/A
  • Price/Book 1.75

Options Overview Details

View History
  • Implied Volatility 208.43% ( -2.85%)
  • Historical Volatility 57.88%
  • IV Percentile 80%
  • IV Rank 42.94%
  • IV High 467.20% on 04/05/24
  • IV Low 13.72% on 12/04/23
  • Put/Call Vol Ratio 0.00
  • Today's Volume 1
  • Volume Avg (30-Day) 61
  • Put/Call OI Ratio 0.03
  • Today's Open Interest 889
  • Open Int (30-Day) 855

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.14
  • Number of Estimates 2
  • High Estimate -0.12
  • Low Estimate -0.15
  • Prior Year -0.05
  • Growth Rate Est. (year over year) -180.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.16 +12.80%
on 11/19/24
4.15 -13.98%
on 11/06/24
-0.19 (-5.05%)
since 11/04/24
3-Month
3.16 +12.80%
on 11/19/24
4.41 -19.05%
on 09/19/24
-0.33 (-8.46%)
since 09/04/24
52-Week
3.16 +12.80%
on 11/19/24
5.55 -35.62%
on 01/12/24
-1.45 (-28.88%)
since 12/04/23

Most Recent Stories

More News
MaxCyte Celebrates 25 Years of Innovation Driving Cell Engineering-Based Therapeutics

MXCN.LN : 680.000 (unch)
MXCT.LN : 275.000 (-1.08%)
MXCT : 3.58 (-0.28%)
MaxCyte Reports Third Quarter 2024 Financial Results and Updates Full Year 2024 Guidance

MXCN.LN : 680.000 (unch)
MXCT.LN : 275.000 (-1.08%)
MXCT : 3.58 (-0.28%)
MaxCyte to Participate in Two Upcoming Investor Conferences

MXCN.LN : 680.000 (unch)
MXCT.LN : 275.000 (-1.08%)
MXCT : 3.58 (-0.28%)
MaxCyte Appoints Cynthia Collins to its Board of Directors

PSTX : 9.31 (-0.21%)
MXCN.LN : 680.000 (unch)
DMTKQ : 0.0001 (unch)
MXCT.LN : 275.000 (-1.08%)
MXCT : 3.58 (-0.28%)
CERT : 11.46 (+1.78%)
MaxCyte to Report Third Quarter 2024 Financial Results on November 6, 2024

MXCN.LN : 680.000 (unch)
MXCT.LN : 275.000 (-1.08%)
MXCT : 3.58 (-0.28%)
MaxCyte Appoints Ali Soleymannezhad as Chief Commercial Officer

MXCN.LN : 680.000 (unch)
MXCT.LN : 275.000 (-1.08%)
MXCT : 3.58 (-0.28%)
Why Shares of MaxCyte Are Plummeting on Thursday

The biotech company reduced full-year guidance and expects so-so third-quarter revenue.

MXCT : 3.58 (-0.28%)
Nasdaq Futures Slip as Bond Yields Rebound, U.S. Jobs Report Looms

December Nasdaq 100 E-Mini futures (NQZ23) are trending down -0.10% this morning after three major U.S. benchmark indices closed higher on Wednesday as the latest batch of U.S. economic data prompted investors...

ESZ23 : 4,694.27s (-0.58%)
NQZ23 : 16,530.23s (-0.07%)
MSFT : 437.59 (+1.48%)
AMZN : 217.60 (+1.95%)
META : 615.14 (+0.24%)
PLTR : 70.15 (-1.14%)
PSX : 133.09 (-1.03%)
MRO : 28.55 (-1.28%)
CALM : 98.25 (-0.40%)
PNDOR.C.DX : 1,189.250 (+0.11%)
MXCT : 3.58 (-0.28%)
BB : 2.61 (+2.76%)
MaxCyte, Inc. (MXCT) Q2 2022 Earnings Call Transcript

MXCT earnings call for the period ending June 30, 2022.

MXCT : 3.58 (-0.28%)
MaxCyte Reports Second Quarter and Half-Year 2022 Financial Results

45% Year-Over-Year Core Business Revenue Growth in Second Quarter 2022 Raises 2022 Core Revenue Growth Guidance to Approximately 30% ROCKVILLE, Md.,...

MXCT : 3.58 (-0.28%)
MXCN.LN : 680.000 (unch)
MXCT.LN : 275.000 (-1.08%)

Business Summary

MaxCyte Inc. is a provider of cell-engineering enabling technology and is responsible cell-based therapies. MaxCyte Inc. is headquartered in Gaithersburg, Maryland.

See More

Key Turning Points

3rd Resistance Point 3.78
2nd Resistance Point 3.70
1st Resistance Point 3.64
Last Price 3.58
1st Support Level 3.51
2nd Support Level 3.43
3rd Support Level 3.37

See More

52-Week High 5.55
Fibonacci 61.8% 4.64
Fibonacci 50% 4.36
Fibonacci 38.2% 4.07
Last Price 3.58
52-Week Low 3.16

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar